Production (Stage)
The Oncology Institute, Inc.
TOI
$3.02
$0.031.00%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 403.15M | 393.41M | 378.93M | 361.07M | 342.71M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 403.15M | 393.41M | 378.93M | 361.07M | 342.71M |
| Cost of Revenue | 343.88M | 339.42M | 325.19M | 305.72M | 285.27M |
| Gross Profit | 59.28M | 54.00M | 53.74M | 55.35M | 57.44M |
| SG&A Expenses | 104.75M | 107.83M | 111.17M | 112.69M | 113.49M |
| Depreciation & Amortization | 6.58M | 6.29M | 6.16M | 6.28M | 6.09M |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 455.21M | 453.53M | 442.52M | 424.69M | 404.85M |
| Operating Income | -52.06M | -60.12M | -63.59M | -63.62M | -62.14M |
| Income Before Tax | -64.36M | -64.66M | -70.55M | -71.72M | -73.04M |
| Income Tax Expenses | -- | -- | -314.00K | -179.00K | -80.00K |
| Earnings from Continuing Operations | -64.36 | -64.66 | -70.24 | -71.54 | -72.96 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -64.36M | -64.66M | -70.24M | -71.54M | -72.96M |
| EBIT | -52.06M | -60.12M | -63.59M | -63.62M | -62.14M |
| EBITDA | -45.48M | -53.83M | -57.43M | -57.34M | -56.05M |
| EPS Basic | -0.74 | -0.76 | -0.82 | -0.84 | -0.86 |
| Normalized Basic EPS | -0.50 | -0.54 | -0.60 | -0.61 | -0.62 |
| EPS Diluted | -0.75 | -0.76 | -0.83 | -0.84 | -0.86 |
| Normalized Diluted EPS | -0.50 | -0.54 | -0.60 | -0.61 | -0.62 |
| Average Basic Shares Outstanding | 303.03M | 300.16M | 297.98M | 295.92M | 295.29M |
| Average Diluted Shares Outstanding | 303.03M | 300.16M | 297.98M | 295.92M | 295.29M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |